CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Rapid manufacturing of non-activated potent CAR T cells.
Rapid manufacturing of non-activated potent CAR T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)T细胞可在B细胞血液系统恶性肿瘤中产生持久的临床应答。这些T细胞的制备通常包括其激活,随后进行病毒转导并在体外扩增至少6天。然而,CAR-T 细胞的激活和扩增会导致其进行性分化以及相关的抗白血病活性丧失。本研究表明,功能性CAR-T 细胞可在24小时内由外周血来源的T细胞生成,无需T细胞激活或体外扩增,并且该过程中病毒转导的效率在很大程度上受培养基配方和培养容器表面积与体积比的影响。在人白血病人小鼠异种移植模型中,快速生成的非激活CAR-T 细胞表现出比使用标准方案制备的相应激活CAR-T 细胞更高的单细胞体内抗白血病活性。CAR-T 细胞的快速制备可能降低生产成本并拓宽其适用性。
Chimaeric antigen receptor (CAR) T cells can generate durable clinical responses in B-cell haematologic malignancies. The manufacturing of these T cells typically involves their activation, followed by viral transduction and expansion ex vivo for at least 6 days.
However, the activation and expansion of CAR T cells leads to their progressive differentiation and the associated loss of anti-leukaemic activity.
Here we show that functional CAR T cells can be generated within 24 hours from T cells derived from peripheral blood without the need for T-cell activation or ex vivo expansion, and that the efficiency of viral transduction in this process is substantially influenced by the formulation of the medium and the surface area-to-volume ratio of the culture vessel.
In mouse xenograft models of human leukaemias, the rapidly generated non-activated CAR T cells exhibited higher anti-leukaemic in vivo activity per cell than the corresponding activated CAR T cells produced using the standard protocol. The rapid manufacturing of CAR T cells may reduce production costs and broaden their applicability.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。